deltatrials
Recruiting PHASE2 INTERVENTIONAL 2-arm NCT04935684

Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation (TMF-Allo)

Faecal Microbiota Transplantation for Prevention of Graft-versus-host Sisease After Allogeneic Stem Cell Transplantation for Haematological Malignancies

Sponsor: French Society of Hematology

Updated 6 times since 2021 Last updated: Feb 28, 2023 Started: Dec 20, 2022 Primary completion: Oct 31, 2026 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acute Leukemia in Remission and Chronic Lymphocytic Leukemia and is currently actively recruiting participants. French Society of Hematology leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2021 – ~Nov 2022 · 14 months · monthly snapshotNot Yet Recruiting~Nov 2022 – ~Apr 2023 · 5 months · monthly snapshotNot Yet Recruiting~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotRecruiting~Sep 2025 – present · 10 months · monthly snapshotRecruiting

Change History

6 versions recorded
  1. Sep 2025 — Present [monthly]

    Recruiting PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Apr 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  5. Nov 2022 — Apr 2023 [monthly]

    Not Yet Recruiting PHASE2

Show 1 earlier version
  1. Sep 2021 — Nov 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • French Society of Hematology
  • Ministry of Health, France
  • University Hospital, Clermont-Ferrand
Data source: University Hospital, Clermont-Ferrand

For direct contact, visit the study record on ClinicalTrials.gov .